The restoration of bestrophin 1 function in patient-derived RPE confirms the US Food and Drug Administration–approved drug 4PBA as a promising therapeutic treatment for bestrophinopathies. The gene discussed is BEST1; the disease is autosomal recessive bestrophinopathy.